Recent News

• 09.08.2025 - H.C. Wainwright 27th Annual Global Investment Conference
• 09.03.2025 - Aldeyra Therapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
• 08.28.2025 - Aldeyra Therapeutics Receives Orphan Designation from the European Medicines Agency for ADX-2191 for the Treatment of Primary Large B-Cell Lymphomas of Immune-Privileged Sites, including Primary Vitreoretinal Lymphoma
• 08.19.2025 - Aldeyra Therapeutics Receives Fast Track Designation for ADX‑2191 for the Treatment of Retinitis Pigmentosa
• 08.13.2025 - H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
• 08.06.2025 - Aldeyra Therapeutics to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
• 07.24.2025 - Aldeyra Therapeutics Receives Orphan Designation from the European Medicines Agency for ADX-2191 for the Treatment of Inherited Retinal Dystrophies including Retinitis Pigmentosa
• 07.17.2025 - Aldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease
• 06.26.2025 - Aldeyra Therapeutics Receives Special Protocol Assessment Agreement Letter from the U.S. Food and Drug Administration for ADX-2191 for the Treatment of Primary Vitreoretinal Lymphoma

Recent Filings

• 08.19.2025 - EX-99.1 EX-99.1
• 08.19.2025 - 8-K Current report
• 08.15.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 08.13.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.12.2025 - 144 Report of proposed sale of securities
• 08.07.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 07.17.2025 - EX-99.1 EX-99.1
• 07.17.2025 - 8-K Current report
• 06.26.2025 - 8-K Current report